Unilateral Nevoid Telangiectasia Treatment & Management

  • Author: Rajani Katta, MD; Chief Editor: Dirk M Elston, MD   more...
 
Updated: Aug 1, 2011
 

Medical Care

In cases of acquired unilateral nevoid telangiectasia, observe for progression or improvement after addressing possible estrogen excess.

In congenital unilateral nevoid telangiectasia or in cases of acquired unilateral nevoid telangiectasia that do not improve, treatment is elective.

If cosmesis is desired, camouflage cosmetics or vascular laser treatment of the involved areas may be helpful.

Next

Surgical Care

Pulsed dye lasers with a wavelength of 585 nm and a pulse width of 450 microseconds offer a safe effective treatment of telangiectases. Use caution in the thinner skin in the neck area to avoid blistering and potential scarring. Cliff and Harland reported their results with the use of pulsed-dye laser in the treatment of 5 patients with unilateral nevoid telangiectasia.[9] They found that pulsed-dye laser was an effective treatment, but they noted a recurrence of lesions in all cases. Sharma and Khandpur, on the other hand, found no recurrence in their 6 Indian patients treated with the 585-nm pulsed dye laser.[10] A moderate response was achieved in all patients, and reversible pigmentary changes were the major adverse effects.

Pulsed-dye lasers with longer wavelengths and pulse widths are now available for larger vessels.

Pulsed KTP (potassium-titanyl-phosphate) 532-nm, long-pulsed alexandrite 755-nm, pulsed diode 800- to 930-nm, long-pulsed Nd:YAG 1064-nm, and filtered broad-spectrum pulsed light sources have been used for vascular lesions, with less postoperative purpura.

Previous
Proceed to Follow-up
 
 
Contributor Information and Disclosures
Author

Rajani Katta, MD  Associate Professor, Department of Dermatology, Baylor College of Medicine; Director, Contact Dermatitis Clinic

Rajani Katta, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Contact Dermatitis Society, and Phi Beta Kappa

Disclosure: Nothing to disclose.

Specialty Editor Board

Abdul-Ghani Kibbi, MD  Professor and Chair, Department of Dermatology, American University of Beirut Medical Center, Lebanon

Disclosure: Nothing to disclose.

Michael J Wells, MD  Associate Professor, Department of Dermatology, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine

Michael J Wells, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, and Texas Medical Association

Disclosure: Nothing to disclose.

Van Perry, MD  Assistant Professor, Department of Medicine, Division of Dermatology, University of Texas School of Medicine at San Antonio

Van Perry, MD is a member of the following medical societies: American Academy of Dermatology and American Society for Laser Medicine and Surgery

Disclosure: Nothing to disclose.

Catherine M Quirk, MD  Clinical Assistant Professor, Department of Dermatology, University of Pennsylvania

Catherine M Quirk, MD is a member of the following medical societies: Alpha Omega Alpha and American Academy of Dermatology

Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD  Director, Ackerman Academy of Dermatopathology, New York

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

References

  1. Happle R. Loss of heterozygosity in human skin. J Am Acad Dermatol. Aug 1999;41(2 Pt 1):143-64. [Medline].

  2. Happle R. Mosaicism in human skin. Understanding the patterns and mechanisms. Arch Dermatol. Nov 1993;129(11):1460-70. [Medline].

  3. Wilkin JK, Smith JG Jr, Cullison DA, Peters GE, Rodriquez-Rigau LJ, Feucht CL. Unilateral dermatomal superficial telangiectasia. Nine new cases and a review of unilateral dermatomal superficial telangiectasia. J Am Acad Dermatol. Apr 1983;8(4):468-77. [Medline].

  4. Hynes LR, Shenefelt PD. Unilateral nevoid telangiectasia: occurrence in two patients with hepatitis C. J Am Acad Dermatol. May 1997;36(5 Pt 2):819-22. [Medline].

  5. Beacham BE, Kurgansky D. Unilateral naevoid telangiectasia syndrome associated with metastatic carcinoid tumour. Br J Dermatol. Jan 1991;124(1):86-8. [Medline].

  6. Uhlin SR, McCarty KS Jr. Unilateral nevoid telangiectatic syndrome. The role of estrogen and progesterone receptors. Arch Dermatol. Mar 1983;119(3):226-8. [Medline].

  7. Kavak A, Kutluay L. Unilateral nevoid telangiectasia and hyperthyroidism: a new association or coincidence?. J Dermatol. May 2004;31(5):411-4. [Medline].

  8. Kreft B, Marsch WC, Wohlrab J. Unilateral nevoid telangiectasia syndrome. Dermatology. 2004;209(3):215-7. [Medline].

  9. Cliff S, Harland CC. Recurrence of unilateral naevoid telangiectatic syndrome following treatment with the pulsed dye laser. J Cutan Laser Ther. Apr 1999;1(2):105-7. [Medline].

  10. Sharma VK, Khandpur S. Unilateral nevoid telangiectasia--response to pulsed dye laser. Int J Dermatol. Aug 2006;45(8):960-4. [Medline].

 
Previous
Next
 
Unilateral nevoid telangiectasia on the neck.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.